Duane Burnett

Founder at Arkuda Therapeutics, Inc.

Health Technology

Profile

Duane Burnett is the founder of Arkuda Therapeutics, Inc., where he holds the title of Chief Technology Officer since 2018.
He is currently working as a Director at Aquinnah Pharmaceuticals, Inc.

Duane Burnett active positions

Companies	Position	Start
Aquinnah Pharmaceuticals, Inc. Aquinnah Pharmaceuticals, Inc. BiotechnologyHealth Technology Aquinnah Pharmaceuticals, Inc. restores the health of people with ALS, Alzheimer?s disease and other neurodegenerative diseases. The company was founded by Glenn Larsen and Ben Wolozin in 2014 and is headquartered in Cambridge, MA.	Director/Board Member	-
Arkuda Therapeutics, Inc. Arkuda Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arkuda Therapeutics, Inc. engages in development of medicines to improve the lives of patients with neurological diseases. It leverages insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. The company was founded by Gerhard Koenig and Duane Burnett in 2018 and is headquartered in Cambridge, MA.	Founder	31/12/2017

All active positions of Duane Burnett

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Duane Burnett's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Aquinnah Pharmaceuticals, Inc. Aquinnah Pharmaceuticals, Inc. BiotechnologyHealth Technology Aquinnah Pharmaceuticals, Inc. restores the health of people with ALS, Alzheimer?s disease and other neurodegenerative diseases. The company was founded by Glenn Larsen and Ben Wolozin in 2014 and is headquartered in Cambridge, MA.	Health Technology
Arkuda Therapeutics, Inc. Arkuda Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arkuda Therapeutics, Inc. engages in development of medicines to improve the lives of patients with neurological diseases. It leverages insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. The company was founded by Gerhard Koenig and Duane Burnett in 2018 and is headquartered in Cambridge, MA.	Health Technology